Achilles Therapeutics plc Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
OPERATING EXPENSES:
Research and development
General and administrative
Total operating expenses
Loss from operations
OTHER INCOME (EXPENSE), NET:
Other income (expense)
Total other income (expense), net
Loss before provision for income taxes
Provision for income taxes
Net loss
Other comprehensive income:
Foreign exchange translation adjustment
Comprehensive loss
Net loss per share attributable to ordinary shareholders—basic and diluted
Weighted average ordinary shares outstanding—basic and diluted
Net loss per share attributable to ordinary shareholders-basic
Net loss per share attributable to ordinary shareholders-diluted
Weighted average ordinary shares outstanding-basic
Weighted average ordinary shares outstanding-diluted

Comments